The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
People discussed their experiences with 0.5 mg daily oral dutasteride for hair loss, with one person not seeing any improvement after 8 months and experiencing side effects like mild gynecomastia and weak erections. They also mentioned using 2.5 mg of oral minoxidil without positive results.
RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.
A user shared that while finasteride improved their hair, it didn't solve all their insecurities, suggesting that self-acceptance is key. Others in the conversation expressed varying opinions, with some feeling that finasteride significantly boosted their confidence and quality of life, while others acknowledged it as a solution to hair loss but not a cure-all for other personal issues.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
A user's 11-month progress using 5mg oral minoxidil for hair loss. The user reported significant hair regrowth, including on the beard and eyebrows, and experienced minor side effects like headaches and increased body hair.
The conversation discusses the potential benefits of sublingual minoxidil for hair loss treatment. It suggests that sublingual minoxidil, which bypasses the liver, may have fewer side effects, greater bioavailability, and could be more effective than oral minoxidil.
The conversation discusses the effectiveness of finasteride and dutasteride in treating hair loss, emphasizing that significant results often take 12-18 months or more. Dutasteride is generally considered superior, with similar or fewer side effects than finasteride, but patience is required for noticeable improvement.
The conclusion of the conversation is that the user started using 5% Minoxidil for hair loss and is happy with the progress. They also mentioned being trans and coming off testosterone, which they believe will help prevent further hair loss. Some users suggested using finasteride as well.
RU58841 combined with finasteride or dutasteride is more effective than RU58841 alone for hair loss. Users suggest combining these with minoxidil and microneedling for better results.
User shared 15-month progress using Oral Dutasteride and Sublingual Minoxidil for hair loss. Treatment improved hair density, now considering hair transplant with fewer grafts.
This conversation details the impressive one year progress of a user's hair loss treatment, which included taking daily doses of dutasteride and minoxidil. Other users shared their own experiences with similar treatments, such as not having any shedding when starting, or having an oily scalp that improved significantly.
The conversation is about a 23-year-old who started treating their hair loss with daily oral dutasteride (0.5mg), oral minoxidil (2.5mg), topical RU58841 (80mg), and weekly microneedling at 1.5mm after seeing others' success stories. Significant improvements have been noted, and there is optimism for even better results in the next 6 months.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Nutrafol, a hair loss supplement, has limited and potentially biased research, with one study showing a 10% increase in hair count for women after 6 months but no significant results for men. The user concludes that cheaper, well-studied options like minoxidil may be more effective, especially for men, given the lack of evidence supporting Nutrafol.
Why the top of the head is affected by hair loss more than other areas, and treatments such as surgery, medications like minoxidil, finasteride, and RU58841 to treat it.
A user is starting a microneedling regimen for hair loss, using Derminator 2, ketoconazole shampoo, castor oil, and multivitamins. They plan to provide monthly updates on their progress.
Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hairfollicles, potentially reducing side effects.
User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.
The conversation is about a person struggling with hair loss and feeling frustrated comparing themselves to friends with thick hair. They started taking 1 mg Finasteride a month ago to address the hair loss.
A 50-year-old Black woman with alopecia areata and traction alopecia is seeking a science-based hair loss routine. Current treatments include spearmint tea for DHT levels and considering PRP.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
Redensyl, a hair loss treatment that has been claimed to be 80% more effective than minoxidil, but users have not experienced any results from using it.
The post and conversation are about skepticism towards HairClone's crowdfunding campaign for a hair loss cure, with users expressing doubt and calling it a scam. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A 23-year-old male has been using 1.25 mg generic finasteride daily for 8 months and is seeing significant hair regrowth, particularly in the crown area. He is considering adding minoxidil to his regimen but is unsure if the improvement is due to the medication or just longer hair.